Clinical Trial Update: A Trial to Assess the Effect of Kidney Impairment on How AMG 133 is Absorbed, Broken Down, and Eliminated by the Body [Phase 1]

View source ↗

Summary

A completed Phase 1 trial from Amgen evaluating how kidney impairment affects the absorption, metabolism, and elimination of AMG 133 in individuals with overwei…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Obesity

Drugs mentioned

• AMG 133

Snippet

Sponsor: Amgen | Conditions: Overweight and Obesity | Phase 1 | Status: COMPLETED